Orthocell Ltd
ASX:OCC
Orthocell Ltd
ASX:OCC
Price:
0.39 AUD
-1.27%
Market Closed
Updated:
May 7, 2024
Section:
Relative Value
The Relative Value of one
OCC
stock under the Base Case scenario is
1
AUD.
Compared to the current market price of 0.39 AUD,
Orthocell Ltd
is
Undervalued by 61%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
OCC
Relative Value
Base Case
1
AUD
Undervaluation 61%
Valuation Multiples
Multiples Across Competitors
OCC Competitors Multiples
Orthocell Ltd Competitors
Orthocell Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Orthocell Ltd
ASX:OCC
|
77.7m AUD | 12.8 | -10.5 | -5.5 | -5.5 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.4B USD | 5.3 | 59.6 | 12.9 | 19.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
160.6B USD | 5.4 | 42.7 | 18.2 | 29.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.6B USD | 8.1 | 27.4 | 22.1 | 24.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.7B USD | 10.5 | 28.7 | 22.9 | 24 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.1B AUD | 6.2 | 35.7 | 21.6 | 26.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.7B USD | 3 | 168.7 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46.8B USD | 9.1 | -7.8 | -8.5 | -7.6 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.2B USD | 3.3 | 27.6 | 14.1 | 17.7 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.2T KRW | 18.5 | 75.1 | 45.9 | 63.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
